Physician profile
Mark P Smith
NPI 1124046735
$3,888.49
in general payments reported to CMS, 2019-2025
16 companies · $640 in 2025
The $640 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $24.97 · 2021: $549 · 2022: $616 · 2023: $783 · 2024: $826 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,085.26 | 2019-2025 | Precision7, Lensx, Total30 |
| Bausch & Lomb Americas INC. | $662.48 | 2022-2025 | Infuse, Biotrue One Day, Vyzulta |
| Coopervision INC. | $380.80 | 2019-2024 | Clariti Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $350.96 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $346.30 | 2019-2023 | Acuvue |
| Abbvie INC. | $231.01 | 2022-2024 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $195.78 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.18 | 2019-2021 | |
| Shire North American Group INC | $133.74 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Harrow Eye, LLC | $73.25 | 2025 | Vevye |
| Glaukos Corporation | $38.67 | 2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $25.48 | 2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $22.49 | 2019 | |
| Biotissue Holdings INC. | $21.00 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $19.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.